Square Pharmaceuticals posted double-digit consolidated revenue and profit growth for the nine months ended March 2025, with strong investment income and robust asset expansion, though operating cash flow per share declined due to absence of prior year one-offs.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.